No Data
No Data
JonesTrading Maintains Actinium(ATNM.US) With Buy Rating, Maintains Target Price $9
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Actinium Pharmaceuticals (ATNM) and Novo Nordisk (NVO)
Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma
Positive Buy Rating for Actinium Pharmaceuticals Driven by Promising Preclinical Data and Strategic Collaborations
Actinium Presents Data Showing ATNM-400 Is More Efficacious Than Pluvicto and Is Highly Efficacious After Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
Actinium Highlights Mutation Agnostic Antileukemic Activity Of Actimab-A Against FLT3, NPM1, KMT2A And TP53 Mutations in AML Models Demonstrating Backbone Potential For Acute Myeloid Leukemia Treatment
Josam456 : any opinion on $Damon (DMN.US)$ ? or is it just a wait and see?
Kobashi : I might go crazy on Jaguar Health because of you man lol
Jaguar8 OP Josam456 : No after hours trading but chart is good. May continue tomorrow. Ill see if i will add it latet
かつやっチョッ : Good morning

MoonGazer かつやっチョッ :
View more comments...